Trials / Completed
CompletedNCT00873210
Study In Patients With Kidney Cancer Treated With Sutent
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 121 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Detailed description
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sutent | 50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2009-04-01
- Last updated
- 2012-11-09
Locations
14 sites across 1 country: Slovakia
Source: ClinicalTrials.gov record NCT00873210. Inclusion in this directory is not an endorsement.